Publication:
Thrombopoietin Receptor Agonists for Severe Thrombocytopenia after Allogeneic Stem Cell Transplantation: Experience of the Spanish Group of Hematopoietic Stem Cell Transplant.

No Thumbnail Available

Date

2019-05-29

Authors

Bento, Leyre
Bastida, José María
García-Cadenas, Irene
García-Torres, Estefania
Rivera, Daniel
Bosch-Vilaseca, Anna
De Miguel, Carlos
Martínez-Muñoz, María Esther
Fernández-Avilés, Francesc
Roldán, Elisa

Advisors

Journal Title

Journal ISSN

Volume Title

Publisher

Metrics
Google Scholar
Export

Research Projects

Organizational Units

Journal Issue

Abstract

Persistent thrombocytopenia is a common complication after allogeneic hematopoietic stem cell transplantation (allo-SCT). Romiplostim and eltrombopag are the currently available thrombopoietin receptor agonists (TPO-RAs), and some studies with very small numbers of cases have reported their potential efficacy in the allo-SCT setting. The present retrospective study evaluated the safety and efficacy of TPO-RAs in 86 patients with persistent thrombocytopenia after allo-HSCT. Sixteen patients (19%) had isolated thrombocytopenia (PT), and 71 (82%) had secondary failure of platelet recovery (SFPR). TPO-RA therapy was started at a median of 127 days (range, 27 to 1177 days) after allo-SCT. The median initial and maximum administered doses were 50 mg/day (range, 25 to 150 mg/day) and 75 mg/day (range, 25 to 150 mg/day), respectively, for eltrombopag and 1 µg/kg (range, 1 to 7 µg/kg) and 5 µg/kg (range, 1 to 10 µg/kg), respectively, for romiplostin. The median platelet count before initiation of TPO-RA therapy was 14,000/µL (range, 1000 to 57,000/µL). Platelet recovery to ≥50,000/µL without transfusion support was achieved in 72% of patients at a median time of 66 days (range, 2 to 247 days). Eighty-one percent of the patients had a decreased number of megakaryocytes before treatment, showing a slower response to therapy (P = .011). The median duration of treatment was 62 days (range, 7 to 700 days). Grade 3-4 adverse events (hepatic and asthenia) were observed in only 2% of the patients. At last follow-up, 81% of patients had discontinued TPO-RAs and maintained response, and 71% were alive. To our knowledge, this is the largest series analyzing the use of TPO-RAs after allo-SCT reported to date. Our results support the efficacy and safety in this new setting. Further prospective trials are needed to increase the level of evidence and to identify predictors of response.

Description

MeSH Terms

Adolescent
Adult
Allografts
Benzoates
Child
Child, Preschool
Female
Hematopoietic Stem Cell Transplantation
Humans
Hydrazines
Infant
Male
Platelet Count
Pyrazoles
Receptors, Fc
Receptors, Thrombopoietin
Recombinant Fusion Proteins
Retrospective Studies
Severity of Illness Index
Spain
Thrombocytopenia
Thrombopoietin

DeCS Terms

CIE Terms

Keywords

Allogeneic stem cell transplantation, Thrombocytopenia, Thrombopoietin receptor agonists

Citation